Budget Reductions Target FDA Field Operations
This article was originally published in The Tan Sheet
President Obama’s fiscal 2016 budget request includes cuts to “low priority” enforcement, surveillance and other activities in the FDA human drugs and biologics programs, but still increases drug and biologics program budgets overall.
You may also be interested in...
FDA requests enough pediatric rare disease priority review voucher user fees to fund three redemptions in fiscal year 2016.
CDER’s Woodcock says the new database will drive risk-based inspection decisions.
Batch failure and other measures commonly tracked by manufacturers could be aggregated into an industry-wide index that FDA would use to help make risk-based inspection decisions.